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Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16,
and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against
experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess
L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or
18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both
heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may
provide broad-spectrum protection. © 2000 Academic Press
t
iOver one hundred human papillomavirus (HPV) geno-
types have been identified (http://hpv-web.lanl.gov/) and are
grouped according to the location and type of disease they
cause; cutaneous types that induce benign plantar warts,
those types associated with the rare inherited disorder
epidermodysplasia verruciformis, and the genital-tropic
HPV types. These genital-tropic human papillomaviruses
are responsible for considerable suffering and morbidity
worldwide. They may be further classified as either “low-
risk” or “high-risk” genotypes by the disease they cause.
The low-risk genotypes, such as HPV6 and 11, cause be-
nign genital warts, condyloma accuminata, whereas high-
risk genital HPVs are the etiologic agent of cervical and a
number of other cancers (7). The high-risk HPV types are
frequently detected in cancers and exhibit transforming and
immortalizing properties in vitro. They are typified by HPV
types 16 and 18, which are detected worldwide in 51 and
12% of intraepithelial neoplasia cases, respectively. Unlike
other HPV types, the genital-tropic HPV types are primarily
sexually transmitted (7).
The papillomavirus capsid comprises two genetically
unrelated proteins called L1 and L2 at an estimated ratio
of 30:1 (20), which represent potential targets for a pro-
phylactic vaccine. L1 is able to self-assemble into virus-
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254like particles (VLPs) that are morphologically and immu-
nologically very similar to virion (12). Vaccination with L1
VLPs induces high titers of conformationally dependent
neutralizing antibodies and is able to protect animals
from homologous experimental infection at both cutane-
ous and mucosal challenge sites (1, 11, 19). Passive
transfer of purified immunoglobulin is sufficient to confer
protection to na¨ive animals, consistent with the hypoth-
esis that high levels of neutralizing antibodies in serum
are sufficient for protection (1, 19). However, the neutral-
izing antibodies to L1 are predominantly type specific
with the exception of the closely related types (.85% L1
amino acid identity) which show weak cross-reactivity (4,
17). Furthermore, vaccination with VLPs or virion derived
from one papillomavirus type does not protect against
experimental infection with heterologous types (1).
L2 is incorporated into VLPs, probably at the capsid
vertices, when coexpressed with L1 (12). Much of L2 is
internal to the capsid and is required for genome encapsi-
dation (16). However, a small portion of L2 is exposed on
the capsid surface and accessible to antibodies (15), a
subset of which are neutralizing (5, 6, 18). L2 is not required
for binding of virions to cell surfaces and neutralizing anti-
serum to L2 does not affect this process (6, 18).
Immunization of rabbits with CRPV L2 amino acids
259–492 fused with l cII protein induced a serum neu-
ralizing titer of 32 (64-fold lower than that obtained by
mmunization with CRPV virions) and was protective








255RAPID COMMUNICATIONond study, rabbits immunized with amino acids 67–488 of
CRPV L2 fused to trpE produced low levels of neutraliz-
ing antibodies (a titer of 10) but were completely pro-
tected from experimental infection (14). Rabbit antiserum
to His6 fusions of full length or amino acids 45–173 of
BPV1 L2 had in vitro neutralization titers of 33 and 1000,
respectively (18). However the relative contributions of
the humoral and cellular immunity in L2 prophylaxis are
unclear (8). While the ability of L2 vaccination to protect
against natural (genital) transmission remains to be de-
termined, L2 is a component of a candidate therapeutic
vaccine for genital warts that is currently in clinical test-
ing (13).
Perhaps the L2 vaccination studies most relevant to
genital HPV infection involve BPV4 that is associated
with alimentary cancer in cattle (3). Immunization of cat-
tle with BPV4 L2 fused to glutathione S-transferase (GST)
elicits in vitro neutralizing antibodies and provides long-
lasting immunity to BPV4 infection (3). Prophylactic vac-
cination with BPV4 L2 was effective at low doses, over
long periods, and using denatured material in alum ad-
juvant, suggesting that this approach might also be fea-
sible against HPVs. The neutralizing epitopes have been
mapped to within polypeptide L2a (amino acids 11–200)
(6), including three immunodominant B cell epitopes rep-
resented by peptides 101–120, 131–151, and 151–170 (3),
consistent with data for BPV1 L2 (18). Furthermore, im-
munization with L2a (3) or these three peptides in com-
bination coupled to KLH was protective, with peptide
131–151 exhibiting a therapeutic effect, but no single
neutralizing epitope was defined (2).
A number of non-neutralizing epitopes on BPV1 L2 (15)
and HPV33 L2 have been defined using monoclonal
antibodies (Mabs). Recently, Kawana et al. (10) generated
three Mabs to HPV16 L2 that neutralized HPV16
pseudovirus infection, and two of these Mab also neu-
tralized HPV6. The epitope recognized by the Mab that
neutralized only HPV16 comprises residues 69–81 of
HPV16 L2, a region that is recognized by antibodies of
patients with genital HPV infections (9, 10). The two
monoclonal antibodies that neutralized both HPV6 and
16 recognized epitopes in residues 108–120 of HPV16 L2,
a region of homology among the genital HPV genotypes
(10). This epitope might be used for development of a
broadly protective prophylactic HPV vaccine.
Published studies of L2 vaccination have only ad-
dressed challenge by homologous papillomavirus type.
At least 15 different high-risk genital HPV types have
been identified in intraepithelial neoplasia which repre-
sent many serotypes (7). Vaccination with VLPs derived
from each serotype would likely be required for complete
protection, making formulation both cumbersome and
expensive. Although neutralizing activity was not tested,
both HPV type-specific and cross-reactive linear
epitopes in L2 have been identified by Western blotting
and ELISA (7). Cross-reactive epitopes on HPV11, 16, 18, nand 33 were identified by Western blot and enzyme-
linked immunosorbent assays (21). These cross-reactive
epitopes occur in a region of L2 likely to be on the
surface of the virion, to contain epitopes recognized by
humans, and to be neutralizing (6, 9, 10, 15, 18). There-
fore, although L2 is less well conserved than L1, we have
examined L2 for potential as a broad specificity prophy-
lactic genital HPV vaccine able to induce neutralizing
antibody to many HPV genotypes. We chose HPV types 6,
16, and 18 for study since they represent both low- and
high-risk genital HPVs, and they are the most common
genital types and are each from distinct phylogenetic
clades, groups A11, A9, and A7, respectively (http://
hpv-web.lanl.gov/).
In Vitro Neutralization of HPV6, 16, and 18 Pseudoviri-
ons. To generate hyperimmune sera, sheep were immu-
nized monthly with 0.1 mg of gel-purified L2 peptides
derived from HPV types 6, 16, and 18, with Freund’s
complete adjuvant to prime, and incomplete adjuvant for
all boosts. HPV16 L2 protein was expressed as two
separate GST-fusion proteins (incorporating aa 1–251
and aa 240–473, respectively), which were gel-purified.
HPV18 L2 protein was also expressed as a GST fusion,
but using the complete sequence. HPV6 L2 protein was
expressed as a TrpE fusion, once again incorporating the
complete L2 sequence. As a negative control, a sheep
was immunized with crude extract of Escherichia coli
that do not express L2 (null). The in vitro neutralization
activity of these sera for BPV1 virions was determined as
described previously (16). Because of difficulties in ob-
taining HPV virion, and consistently and quantitatively
assaying infectivity we adopted a pseudovirion strategy,
in which HPV capsid proteins are used to package the
BPV1 genome that may be detected in vitro by focal
transformation of mouse fibroblasts. We have previously
applied this methodology to HPV16, to generate
HPV16{BPV1} pseudovirions (16). HPV6 L1 and L2 were
PCR-amplified from HPV6 virus DNA (a kind gift of Dr.
William Bonnez, Rochester) and cloned into pSFV4.2
(generously donated by Dr. Joel Jessie, Life Technolo-
gies, Gaithersburg, MD) and pSFV1 expression vectors,
respectively, from which recombinant SFV were pro-
duced and used to generate HPV6{BPV1} pseudovirions,
as for HPV16{BPV1} (16). The same procedure was also
applied to generate HPV18{BPV1} pseudovirions. The
ability of antisera from rabbits immunized three times
with 300 mg of L1/L2 VLPs derived from HPV types 6b, 11,
6, 18, 31 (L1 only), 33, and 45 (17) to neutralize these
seudovirion preparations in vitro was determined (Table
). High neutralization titers toward viruses of the same
ype as that used to generate the VLP-specific sera,
eak neutralization by very closely related types from
ithin the same phylogenetic clade, e.g. HPV6 and 11,
PV18, and 45 (http://hpv-web.lanl.gov/), and absence of
















256 RAPID COMMUNICATIONis consistent with previous hemagglutination inhibition
and neutralization data (4, 16, 17). Note that even antisera
to VLPs containing L2 are not cross-neutralizing between
HPV phylogenetic clades.
L2 Antibodies Cross-Neutralize Genital HPVs. The abil-
ity of sheep antiserum to HPV6, 16, and 18 L2 to neutral-
ize these types in vitro was determined (Table 1). Con-
istent with studies of animal papillomaviruses, in each
ase the L2 antiserum was able to most strongly neu-
ralize the homologous HPV virion type. The titers were
0-fold lower than those obtained with rabbit antiserum
o the homologous VLPs; nevertheless animal studies
ndicate that this is sufficient to confer protection (6).
ross-neutralizing titers were 2–3 orders of magnitude
ower than those induced by the homologous VLP type.
he inability of HPV L2 antisera to neutralize BPV1 (ex-
ept a 10-fold dilution of HPV18 L2 antiserum) or to
eutralize HPV pseudovirions when preincubated with
urified L2 protein (Fig. 1) demonstrates that inhibition of
nfection is L2 antibody-mediated. Further, neither preim-
une serum nor immune serum to control E. coli extract
TABLE 1
In Vitro Neutralization of HPV Pseudovirions and BPV1 by Antisera
to Papillomavirus Capsid Proteins
Antiserum HPV6{BPV1} HPV16{BPV1} HPV18{BPV1} BPV1
Null E. coli extract† ,10 ,10 ,10 ,10
Null E. coli
extract*,† ,10 ,10 ,10 ,10
HPV6 L2*,† 1000 33 33 ,10
HPV16 L2† 100 1000 33 ,10
HPV16 L2*,† 100 330 33 ,10
HPV18 L2† 1000 330 1000 10
HPV6 L1 1 L2 VLP 33,000 ,10 ,10 ND
HPV11 L1 1 L2
VLP 1000 ,10 ,10 ND
HPV16 L1 1 L2
VLP 10 33,000 ,10 ND
HPV18 L1 1 L2
VLP ,10 ,10 33,000 ND
HPV31 L1 VLP ,10 ,10 ,10 ND
HPV33 L1 1 L2
VLP ,10 ,10 ,10 ND
HPV45 L1 1 L2
VLP ,10 ,10 10 ND
Note. HPV pseudovirions or BPV1 were incubated with titrated anti-
sera for 1 h on ice and then incubated with mouse C127 cell mono-
layers for 1 h at 37°C. The C127 cells were maintained for 3 weeks and
stained, and the foci counted. Titers indicate the reciprocal dilution that
inhibits focus formation by approximately 50%. No neutralization of
HPV6, 16, or 18 pseudovirion or BPV1 was observed with a 1:10 dilution
of preimmunization sera for each antiserum described.
Rabbit antiserum was used except for samples (†) in which sheep
antisera were used. *Indicates that antibody purified from serum by
capryllic acid precipitation and DEAE ion-exchange chromatography
was used at 8 mg/ml for the in vitro neutralization assay.eutralized at 1:10 dilution (Table 1). Interestingly, cross-neutralization between genital HPV types, but not of
BPV1, was also observed (Table 1). This suggests that
immunization with L2 derived from one genital HPV type
may be sufficient to confer significant protection from
infection by other genital HPVs, but not other papilloma-
virus types, consistent with serologic data (22) and Mab
studies (10).
It is surprising that immunization with VLPs containing
L2 does not also provide cross-neutralizing antibodies.
Perhaps the relevant epitopes of L2 are masked by the
capsid except during infection, resulting in poor presen-
tation to the immune system (3). Alternatively, the highly
immunogenic nature of the regularly spaced L1 epitopes
might dominate the humoral response. Poor antibody
response to L2 was also observed upon infection with
BPV, CRPV, and HPV (3, 22). Finally, the lack of cross-
neutralizing antibody may result from a lower dose of
immunogen; 300 mg of L1/L2 VLP, containing ;10 mg of
L2, was injected each immunization as compared to 100
mg of L2 gel-purified polypeptide.
In conclusion, we have demonstrated that L2 of genital
HPV types 6, 16, and 18 contains subdominant cross-
neutralizing epitopes. This is the first study to demon-
FIG. 1. Anti-HPV6 L2 serum-mediated neutralization of HPV18
pseudovirions is prevented by preincubation with purified HPV6 L2E7
protein. Anti-HPV6 L2 antibody was incubated with 100 mg of purified
HPV6 L2-E7-fusion protein or buffer alone for 1 h on ice and then mixed
with HPV18{BPV1} pseudovirions for a further hour on ice. The samples
were incubated with monolayers of mouse C127 cells for 1 h at 37°C,
the cells were washed and maintained for 3 weeks in complete me-
dium, and the foci were stained. (A) HPV18{BPV1} pseudovirions alone.
(B) HPV18{BPV1} pseudovirions preincubated with 1:100 rabbit anti-
serum to HPV18 L1/L2 VLPs, (C) HPV18{BPV1} pseudovirions preincu-
bated with 1:10 sheep antibody to HPV6 L2, (D) HPV18{BPV1}
pseudovirions preincubated with 1:10 sheep antibody to HPV6 L2 plus
100 mg of purified HPV6 L2-E7-fusion protein.
257RAPID COMMUNICATIONstrate generation of broadly cross-neutralizing antisera
after vaccination with a specific papillomavirus immuno-
gen derived from a single HPV genotype. It is particularly
noteworthy that cross-neutralization was detected for the
representatives of two major clades of high-risk genital-
tropic HPV. While cross-neutralizing titers were be-
tween 33 and 330, this may be sufficient for protection.
Immunization with bacterially expressed CRPV L2 elic-
ited neutralizing titers of 10 (14) and 32 (5), yet rabbits
were protected from experimental CRPV infection. Simi-
larly, vaccination with bacterially expressed GST-BPV4
L2 elicited serum antibody neutralizing at a titer of 5 in
cattle protected from BPV4 infection of the soft palate (6).
Evidence that L2 vaccination protects animals from ex-
perimental infection (3, 14) and that cross-neutralizing
epitopes exist in HPV L2 (our studies and (10)) suggest
that further study of L2 as a broad spectrum, prophylactic
genital HPV vaccine is warranted. Such a vaccine has
several theoretical advantages; it should be easy and
cheap to produce and could be safely used with alum
adjuvant since ongoing studies have proven bacterially
expressed HPV6 L2-E7 well tolerated in humans (13). We
intend to further define the nature of the cross-reactive
epitopes of L2 using patient sera (13) and refine them to
an HPV L2 consensus sequence that might be even
more broadly cross-neutralizing and immunogenic.
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